Suppression of the nitric oxide pathway in metastatic renal cell carcinoma patients receiving vascular endothelial growth factor-signaling inhibitors.
about
Combination therapy in cancer: effects of angiogenesis inhibitors on drug pharmacokinetics and pharmacodynamicsThe Potential Role of Nitric Oxide in Halting Cancer Progression Through ChemopreventionVascular Complications of Cancer ChemotherapyIncidence and risk of hypertension with bevacizumab in non-small-cell lung cancer patients: a meta-analysis of randomized controlled trialsPonatinib reduces viability, migration, and functionality of human endothelial cells.Optical imaging for monitoring tumor oxygenation response after initiation of single-agent bevacizumab followed by cytotoxic chemotherapy in breast cancer patients.Correlation of hypertension and proteinuria with outcome in elderly bevacizumab-treated patients with metastatic colorectal cancer.Hypertension among patients with renal cell carcinoma receiving axitinib or sorafenib: analysis from the randomized phase III AXIS trialContrary effects of the receptor tyrosine kinase inhibitor vandetanib on constitutive and flow-stimulated nitric oxide elaboration in humansManagement of antiangiogenic therapy-induced hypertension.Anti-proliferative effect of Flos Albiziae flavonoids on the human gastric cancer SGC-7901 cell line.Regorafenib induces rapid and reversible changes in plasma nitric oxide and endothelin-1Therapeutic potential of nitric oxide donors in the prevention and treatment of angiogenesis-inhibitor-induced hypertensionCardiovascular complications associated with novel angiogenesis inhibitors: emerging evidence and evolving perspectives.Bevacizumab use and risk of cardiovascular adverse events among elderly patients with colorectal cancer receiving chemotherapy: a population-based study.Soluble fms-like tyrosine kinase 1 promotes angiotensin II sensitivity in preeclampsia.Early detection of antiangiogenic treatment responses in a mouse xenograft tumor model using quantitative perfusion MRI.Sunitinib, hypertension, and heart failure: a model for kinase inhibitor-mediated cardiotoxicity.Antiangiogenic-induced hypertension: the molecular basis of signaling network.Is the toxicity of anti-angiogenic drugs predictive of outcome? A review of hypertension and proteinuria as biomarkers of response to anti-angiogenic therapy.Vascular endothelial growth factor inhibitor-induced hypertension: from pathophysiology to prevention and treatment based on long-acting nitric oxide donors.Renal cell carcinoma: new insights and challenges for a clinician scientist.Hypertension Induced by Tyrosine-Kinase Inhibitors for the Treatment of Renal Cell Carcinoma in Hemodialysis Patients: A Single-Center Experience and Review of the Literature.Adverse events of monoclonal antibodies used for cancer therapy.Antiangiogenic Therapy for Diabetic Nephropathy.Effects of 4 multitargeted receptor tyrosine kinase inhibitors on regional hemodynamics in conscious, freely moving rats.Management of metastatic renal cell carcinoma in the era of targeted therapies.Renin angiotensin system deregulation as renal cancer risk factor.Cardio-Oncology: mechanisms of cardiovascular toxicity.Mechanisms of VEGF (Vascular Endothelial Growth Factor) Inhibitor-Associated Hypertension and Vascular Disease.Hypertension in malignancy-an underappreciated problem.Research progress on common adverse events caused by targeted therapy for colorectal cancer.
P2860
Q26746067-37E907AB-B89F-4A48-98A5-9D651E417C2EQ26751142-090DEFF0-2294-4AE4-A2CE-C933F6A0BDE1Q26766269-56D7CC49-DF9F-49A8-A4E8-0F3EFE1E168EQ26796456-7DE43B6F-F0E6-4040-8F7F-3CA4669022B3Q33364077-D42A8F60-6850-4D76-9F33-B92582B72436Q33721539-73681AEB-41DC-4BA7-93EB-0BE6E750FF82Q34989562-125B5702-81FB-4504-8A59-80DE40D78530Q35187848-E0D56582-393D-4BBC-892E-58BB1323EDC9Q36100725-E7373FAC-B6A4-4A4D-A6CE-6FDAA7616403Q36170252-D187B8C0-6634-48F4-88AE-C18F59ACA77DQ36472059-79C6399A-5955-4E30-84DE-104AC9DFDD0DQ36627125-D32BEFCE-14A1-4D50-8029-2A1944EB74D4Q36678295-520CCC02-5AA1-43C6-A5ED-2D46F35CE193Q36751861-2F19CB71-0D97-41AD-9F8A-0D876F143389Q36862836-9968954D-6424-4E03-807D-DA304521E55BQ37042332-0A072139-82B6-4DBF-8051-B8D51AABD685Q37595237-AA4D3CC6-E85B-4033-A657-540D59D5CEF6Q37935596-DBAD1D00-1BDD-4C24-9728-854414491FD2Q37973600-9306D9A5-9850-49CB-91A5-590D31B8EE49Q37979314-159FA0C2-3F68-497F-9BC2-FA595A59E82DQ38156262-773EDC53-F3C3-4EBB-B3B8-252E7328F5D8Q39222755-E7AE45FD-AC09-4F8A-B623-757CC830A1EEQ39330209-3FA1EAFD-37C8-47EA-914F-30687C201D79Q40812370-13059A18-D718-4F8E-B5EF-34BF9B9AFF2CQ41403094-EC2A71F4-7B1F-4C3D-BA82-17D550BDBDD9Q42323403-52BAE6AA-B8D4-4C86-A3A6-ACBE89A12AF9Q44225494-7F497FBC-72E5-4FB3-B419-B7BCA8D3BE34Q47094986-BBF7DB09-DC52-44AC-8319-3539DF0E1489Q48109228-C42B6CF3-FB70-487D-BD85-171D16D0778CQ49568718-65AA9FC3-B5D5-4051-89EA-624980260150Q55071881-FE34780D-9C05-4671-B7A8-20A75637651AQ55360813-98C697CC-90A2-4563-8B65-8E3346BBD8C0
P2860
Suppression of the nitric oxide pathway in metastatic renal cell carcinoma patients receiving vascular endothelial growth factor-signaling inhibitors.
description
2010 nî lūn-bûn
@nan
2010 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Suppression of the nitric oxid ...... h factor-signaling inhibitors.
@ast
Suppression of the nitric oxid ...... h factor-signaling inhibitors.
@en
Suppression of the nitric oxid ...... h factor-signaling inhibitors.
@nl
type
label
Suppression of the nitric oxid ...... h factor-signaling inhibitors.
@ast
Suppression of the nitric oxid ...... h factor-signaling inhibitors.
@en
Suppression of the nitric oxid ...... h factor-signaling inhibitors.
@nl
prefLabel
Suppression of the nitric oxid ...... h factor-signaling inhibitors.
@ast
Suppression of the nitric oxid ...... h factor-signaling inhibitors.
@en
Suppression of the nitric oxid ...... h factor-signaling inhibitors.
@nl
P2093
P2860
P1433
P1476
Suppression of the nitric oxid ...... h factor-signaling inhibitors.
@en
P2093
Benjamin D Humphreys
Eliyahu V Khankin
Emily S Robinson
Mallika S Dhawan
Miranda J Rogers
Toni K Choueiri
P2860
P304
P356
10.1161/HYPERTENSIONAHA.110.160481
P407
P577
2010-10-18T00:00:00Z